Dr. Jamshid Ghajar MD, PhD, FACS, Moghadam Family Director, Stanford Brain Performance Center, Clinical Professor of Neurosurgery, Stanford University School of Medicine:

“Darmiyan’s AI, machine learning algorithm using unique MRI microscopic pixel analysis with macroscopic input has generated a very sensitive and specific five year prognosis for patients presenting with amnestic MCI. This technology has high test retest reliability and can be applied to any clinical grade MRI which is a very useful clinical tool to assist doctors advising patients with early memory complaints. In addition the BrainSee degeneration maps clearly show focal areas of degeneration. I believe this will be a widely used technology to assist doctors and patients navigating the difficult terrain of MCI.”

Dr. Bradley Buchsbaum, PhD. Cognitive Neuroscience Associate Professor at University of Toronto, Senior Scientist at Baycrest Institute & Rotman Institute, and Principal Investigator of Darmiyan-CABHI validation project:

“I became interested in Darmiyan when I joined CABHI as a scientific adviser in 2018. In my own research as a cognitive neuroscientist I used functional neuroimaging to study the brain basis of human memory and how it changes with age. Darmiyan’s vision excited me because it offers a biologically-based, objective, and sensitive method for detecting changes in the brain that may first show up as subtle changes in memory and cognition and later, as neurodegenerative disease progresses, lead to more serious cognitive and functional deficits. The promise of a new tool that can give patients and their doctors a head start in planning for—and possibly even heading off—the advance of dementia is exactly what is needed right now, as the aging population grows larger. With the successful conclusion of this project, Darmiyan moves a step closer to delivering on this promise.”

Dr. Michael G. Harrington, MB, ChB, FRCP, Scientific Director of Neuroscience, Huntington Medical Research Institutes, Pasadena, CA: 

“I am the PI of a longitudinal Brain Aging Study at HMRI for more than ten years. Our goal is to identify prodromal biomarkers and potential mechanisms of early dementia pathology of the Alzheimer type. Objective measures such as Darmiyan’s BrainSee that can predict cognitive decline are strongly needed to recognize and monitor potential therapies. I have interacted with Darmiyan for over two years, sharing some of the data from our Brain Aging study participants. I am excited by the potential for objective ways such as Darmiyan’s approach to predict cognitive decline, which can lead to better outcomes for patients and the healthcare system.”  

Dr. David J. Mikulis, MD, Professor and Director of the JDMI Functional Neuroimaging Research Lab and Senior Scientist, Krembil Research Institute at the University Health Network, The Toronto Western Hospital, and the University of Toronto: 

“As a member of the research team that evaluated Darmiyan’s solution for predicting conversion of cognitive impairment to Alzheimer’s dementia, I was impressed by the potential of this breakthrough technology. All study investigators are optimistic that the solution will be successful providing a much needed predictor of disease progression. It may therefore fill a significant diagnostic gap highly valued by patients, clinicians, and clinical researchers.”